Screener
Recursion Pharmaceuticals, Inc. RXRX Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Grant revenue | 367 | 120 | 538 | 47 |
| Total revenue | 7,670 | 19,223 | 14,143 | 33,968 |
| Operating costs and expenses | ||||
| Cost of revenue | 11,491 | 20,161 | 23,981 | 41,990 |
| Research and development | 89,614 | 128,636 | 177,510 | 258,269 |
| General and administrative | 41,533 | 46,653 | 76,124 | 101,304 |
| Total operating costs and expenses | 142,638 | 195,450 | 277,615 | 401,563 |
| Loss from operations | (134,968) | (176,227) | (263,472) | (367,595) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s total cost of revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total cost of revenue of $11.49M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s total cost of revenue changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total cost of revenue decreased by 43.0% year-over-year, from $20.16M to $11.49M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Recursion Pharmaceuticals, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude